Search results for "microRNA"

showing 10 items of 577 documents

Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease—results from the large AtheroGene study

2016

Introduction Stratification for subsequent coronary events among patients with coronary artery disease (CAD) is of considerable interest because of the potential to guide secondary preventive therapies. Recently, we identified eight microRNAs (miRNAs), which facilitated acute coronary syndrome (ACS) diagnosis. In this study, we aimed to evaluate their potential role as prognostic biomarkers for cardiovascular disease. Methods The serum concentrations of eight candidate miRNAs -miR-19a, miR-19b, miR-132, miR-140-3p, miR-142-5p, miR-150, miR-186, and miR-210 were measured in a cohort of 1112 patients with documented CAD—including 430 patients with ACS and 682 patients with stable angina pecto…

0301 basic medicinemedicine.medical_specialtyAcute coronary syndromePathologyProportional hazards modelbusiness.industryDisease030204 cardiovascular system & hematologymedicine.diseaseCoronary artery disease03 medical and health sciencesCirculating MicroRNA030104 developmental biology0302 clinical medicineInternal medicineCohortmedicineCardiologyBiomarker (medicine)Cardiology and Cardiovascular MedicineRisk assessmentbusinessEuropean Heart Journal
researchProduct

Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect

2020

Liraglutide has shown favourable effects on several cardiometabolic risk factors, beyond glucose control. MicroRNAs (miRNAs) regulate gene expression, resulting in post-transcriptional modifications of cell response and function. Specific miRNAs, including miRNA-27b, miRNA-130a, and miRNA-210, play a role in cardiometabolic disease. We aimed to determine the effect of liraglutide on the serum levels of miRNA-27b, miRNA-130a and miRNA-210. Twenty-five subjects with type-2 diabetes mellitus (T2DM), na&iuml

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and Metabolismlcsh:QR1-502IncretinType 2 diabetestype-2 diabetes030204 cardiovascular system & hematologyBiochemistryArticlelcsh:Microbiologyliraglutide; microRNAs; type-2 diabetes; cardiometabolic risk; epigenetic03 medical and health sciences0302 clinical medicineInterquartile rangeDiabetes mellitusInternal medicinecardiometabolic riskMedicineMolecular Biologyliraglutidebusiness.industryLiraglutideType 2 Diabetes MellitusMicroRNAmedicine.diseaseMetforminmicroRNAs030104 developmental biologyEndocrinologybusinessHomeostasisepigeneticmedicine.drugMetabolites
researchProduct

MicroRNAs in Muscle: Characterizing the Powerlifter Phenotype

2017

Powerlifters are the epitome of muscular adaptation and are able to generate extreme forces. The molecular mechanisms underpinning the significant capacity for force generation and hypertrophy are not fully elucidated. MicroRNAs (miRs) are short non-coding RNA sequences that control gene expression via promotion of transcript breakdown and/or translational inhibition. Differences in basal miR expression may partially account for phenotypic differences in muscle mass and function between powerlifters and untrained age-matched controls. Muscle biopsies were obtained from m. vastus lateralis of 15 national level powerlifters (25.1 ± 5.8 years) and 13 untrained controls (24.1 ± 2.0 years). The …

0301 basic medicinemedicine.medical_specialtyPhysiologymRNAMyostatinMyoDlcsh:PhysiologyMuscle hypertrophy03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicineGene expressionmicroRNAmedicineskeletal muscleOriginal ResearchGeneticsMessenger RNAlcsh:QP1-981biologymicroRNASkeletal musclePhenotype030104 developmental biologymedicine.anatomical_structureEndocrinologybiology.proteingene expressionresistance training030217 neurology & neurosurgeryFrontiers in Physiology
researchProduct

2020

Background To date, microRNAs (miRs) carried in extracellular vesicles (EVs) in response to exercise have been studied in blood but not in non-invasively collectable body fluids. In the present study, we examined whether six exercise-responsive miRs, miRs-21, -26, -126, -146, -221, and -222, respond to acute endurance exercise stimuli of different intensities in sweat. Methods We investigated the response of miRs isolated from sweat and serum EVs to three endurance exercise protocols: (1) maximal aerobic capacity (VO2max ), (2) anaerobic threshold (AnaT), and (3) aerobic threshold (AerT) tests. Sauna bathing was used as a control test to induce sweating through increased body temperature in…

0301 basic medicinemedicine.medical_specialtyintegumentary systemCD63Physiologybusiness.industryVO2 max030204 cardiovascular system & hematologyExtracellular vesiclesSWEAT03 medical and health sciencesSauna bathing030104 developmental biology0302 clinical medicineEndocrinologyEndurance trainingPhysiology (medical)Internal medicinemicroRNAMedicinebusinessAnaerobic exerciseFrontiers in Physiology
researchProduct

MiR675-5p Acts on HIF-1α to Sustain Hypoxic Responses: A New Therapeutic Strategy for Glioma

2016

Hypoxia is a common feature in solid tumours. In glioma, it is considered the major driving force for tumour angiogenesis and correlates with enhanced resistance to conventional therapies, increased invasiveness and a poor prognosis for patients. Here we describe, for the first time, that miR675-5p, embedded in hypoxia-induced long non-coding RNA H19, plays a mandatory role in establishing a hypoxic response and in promoting hypoxia-mediated angiogenesis. We demonstrated, in vitro and in vivo, that miR675-5p over expression in normoxia is sufficient to induce a hypoxic moreover, miR675-5p depletion in low oxygen conditions, drastically abolishes hypoxic responses including angiogenesis. In …

0301 basic medicinemiRNA675AngiogenesisMedicine (miscellaneous)RNA-binding proteinAngiogenesis; Glioma; HuR; Hypoxia; miRNA675; Optical imaging; VHL; Medicine (miscellaneous); Pharmacology Toxicology and Pharmaceutics (miscellaneous)BiologyToxicology and Pharmaceutics (miscellaneous)Cell LineELAV-Like Protein 1Miceoptical imaging03 medical and health sciencesSettore BIO/13 - Biologia ApplicataStress PhysiologicalIn vivoVHLGliomamicroRNAmedicineAnimalsHumansPharmacology Toxicology and Pharmaceutics (miscellaneous)PharmacologyAngiogenesis; HuR; VHL.; glioma; hypoxia; miRNA675; optical imagingMessenger RNANeovascularization PathologichypoxiaVHL.RNAGliomaHypoxia (medical)Hypoxia-Inducible Factor 1 alpha Subunitmedicine.disease3. Good healthAngiogenesiMicroRNAs030104 developmental biologyImmunologyCancer researchHeterograftsHuRAngiogenesismedicine.symptomResearch PaperTheranostics
researchProduct

miR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models

2018

Functional depletion of the alternative splicing factors Muscleblind-like (MBNL 1 and 2) is at the basis of the neuromuscular disease myotonic dystrophy type 1 (DM1). We previously showed the efficacy of miRNA downregulation in Drosophila DM1 model. Here, we screen for miRNAs that regulate MBNL1 and MBNL2 in HeLa cells. We thus identify miR-23b and miR-218, and confirm that they downregulate MBNL proteins in this cell line. Antagonists of miR-23b and miR-218 miRNAs enhance MBNL protein levels and rescue pathogenic missplicing events in DM1 myoblasts. Systemic delivery of these “antagomiRs” similarly boost MBNL expression and improve DM1-like phenotypes, including splicing alterations, histo…

0301 basic medicinemusculoskeletal diseasesMalecongenital hereditary and neonatal diseases and abnormalitiesScienceMyoblasts SkeletalGeneral Physics and AstronomyMice TransgenicBiologyMyotonic dystrophyGeneral Biochemistry Genetics and Molecular BiologyArticleCell Line03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicineRNA interferencemicroRNAmedicineMBNL1Gene silencingAnimalsHumansMyotonic DystrophyGene SilencingRNA Messengerlcsh:ScienceMuscle Skeletal3' Untranslated RegionsMultidisciplinaryThree prime untranslated regionAlternative splicingQRNA-Binding ProteinsGeneral Chemistrymedicine.diseaseMyotoniaCell biologyUp-RegulationAlternative SplicingDisease Models AnimalMicroRNAs030104 developmental biologyPhenotypechemistrylcsh:Q030217 neurology & neurosurgeryHeLa CellsNature Communications
researchProduct

Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy

2020

Myotonic dystrophy type 1 (DM1) is a chronically debilitating, rare genetic disease that originates from an expansion of a noncoding CTG repeat in the dystrophia myotonica protein kinase (DMPK) gene. The expansion becomes pathogenic when DMPK transcripts contain 50 or more repetitions due to the sequestration of the muscleblind-like (MBNL) family of proteins. Depletion of MBNLs causes alterations in splicing patterns in transcripts that contribute to clinical symptoms such as myotonia and muscle weakness and wasting. We previously found that microRNA (miR)-23b directly regulates MBNL1 in DM1 myoblasts and mice and that antisense technology (“antagomiRs”) blocking this microRNA (miRNA) boost…

0301 basic medicinemusculoskeletal diseasescongenital hereditary and neonatal diseases and abnormalitiesMyotonic dystrophyArticleantagomiR03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug DiscoverymicroRNAMedicineMBNL1AntagomirProtein kinase AmiRNAmyotonic dystrophybusiness.industrylcsh:RM1-950Muscle weaknessmedicine.diseaseMyotoniaMbnl1030104 developmental biologylcsh:Therapeutics. Pharmacologychemistry030220 oncology & carcinogenesisRNA splicingCancer researchHSALR miceMolecular Medicinemedicine.symptomDM1antisense oligonucleotidesbusinessMolecular Therapy: Nucleic Acids
researchProduct

Characterization of Differentially Expressed Circulating miRNAs in Metabolically Healthy versus Unhealthy Obesity

2021

Obese individuals without metabolic comorbidities are categorized as metabolically healthy obese (MHO). MicroRNAs (miRNAs) may be implicated in MHO. This cross-sectional study explores the link between circulating miRNAs and the main components of metabolic syndrome (MetS) in the context of obesity. We also examine oxidative stress biomarkers in MHO vs. metabolically unhealthy obesity (MUO). We analysed 3536 serum miRNAs in 20 middle-aged obese individuals: 10 MHO and 10 MUO. A total of 159 miRNAs were differentially expressed, of which, 72 miRNAs (45.2%) were higher and 87 miRNAs (54.7%) were lower in the MUO group. In addition, miRNAs related to insulin signalling and lipid metabolism pat…

0301 basic medicineobesitymedicine.medical_specialtyatherogenic dyslipidaemiaMedicine (miscellaneous)Context (language use)Biologymedicine.disease_causeArticlemetabolic syndromeGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineInsulin resistanceDownregulation and upregulationinsulin resistanceInternal medicinemicroRNAmedicineoxidative stresslcsh:QH301-705.5Lipid metabolismmedicine.diseaseObesitymicroRNAs030104 developmental biologyEndocrinologylcsh:Biology (General)030220 oncology & carcinogenesisMetabolic syndromeOxidative stressBiomedicines
researchProduct

Regulation of Alpha-Secretase ADAM10 In vitro and In vivo: Genetic, Epigenetic, and Protein-Based Mechanisms

2017

ADAM10 (A Disintegrin and Metalloproteinase 10) has been identified as the major physiological alpha-secretase in neurons, responsible for cleaving APP in a non-amyloidogenic manner. This cleavage results in the production of a neuroprotective APP-derived fragment, APPs-alpha, and an attenuated production of neurotoxic A-beta peptides. An increase in ADAM10 activity shifts the balance of APP processing towards APPs-alpha and protects the brain from amyloid deposition and disease. Thus, increasing ADAM10 activity has been proposed an attractive target for the treatment of neurodegenerative diseases and it appears to be timely to investigate the physiological mechanisms regulating ADAM10 expr…

0301 basic medicinepromoterADAM10agingADAM10ReviewBiologyAlzheimer's diseaseNeuroprotectionspineProtein–protein interaction03 medical and health sciencesCellular and Molecular Neuroscience030104 developmental biologyAlpha secretaseIn vivoalpha-secretasetranscription factorsmicroRNAmouse modelsEpigeneticsNeuroscienceTranscription factorMolecular BiologyNeuroscienceFrontiers in Molecular Neuroscience
researchProduct

Menopause and adipose tissue: miR-19a-3p is sensitive to hormonal replacement

2018

Tissue-specific effects of 17 beta-estradiol are delivered via both estrogen receptors and microRNAs (miRs). Menopause is known to affect the whole-body fat distribution in women. This investigation aimed at identifying menopause-and hormone replacement therapy (HRT)-associated miR profiles and miR targets in subcutaneous abdominal adipose tissue and serum from the same women. A discovery phase using array technology was performed in 13 women, including monozygotic twin pairs discordant for HRT and premenopausal young controls. Seven miRs, expressed in both adipose tissue and serum, were selected for validation phase in 34 women from a different cohort. An age/menopause-related increase of …

0301 basic medicinevaihdevuodetmedicine.medical_treatmentmenopauseAdipose tissueEstrogen receptorMonozygotic twinTHERAPYchemistry.chemical_compoundestrogen therapyAdipocyteTUMOR-SUPPRESSORADIPOCYTE DIFFERENTIATIONmicroRNAestrogeenihoitota3141miR-19a-3pHormone replacement therapy (menopause)ta31423142 Public health care science environmental and occupational healthmicroRNAsadipose tissueMenopauseOncologyhormonihoitoSKELETAL-MUSCLEESTROGEN-RECEPTOR-ALPHASTEM-CELLSResearch PaperEXPRESSIONestrogeenitmedicine.medical_specialtyBODY-COMPOSITION3122 Cancersrasvakudokset03 medical and health sciencesInternal medicinemedicineBREAST-CANCERbusiness.industryagingmedicine.diseasehormonitMONOZYGOTIC TWIN PAIRSikääntyminen030104 developmental biologyEndocrinologychemistrybusinessEstrogen receptor alphaHormoneOncotarget
researchProduct